trending Market Intelligence /marketintelligence/en/news-insights/trending/vObr1MNiwMv7AnvpKM2xVQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Leap grants BeiGene option to license experimental cancer treatment

StreetTalk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Leap grants BeiGene option to license experimental cancer treatment

Leap Therapeutics Inc. agreed to grant BeiGene Ltd. an option to obtain an exclusive license for the development and commercialization of its experimental drug DKN-01 for $3 million up front.

Under the agreement, BeiGene will make an additional payment at the time of exercising the option and will acquire rights to develop and commercialize DKN-01 in Australia, New Zealand and Asia, excluding Japan.

Cambridge, Mass.-based Leap will be eligible to receive up to $132 million based on certain development, regulatory and sales milestones. Additionally, BeiGene will pay Leap royalties on the sales of DKN-01 in the region.

Concurrently, BeiGene will make a $5 million investment in Leap as part of a larger equity financing agreement that also includes two institutional investors.

Leap will sell 1,421,801 Series A convertible preferred shares to the lead investor and 1,137,442 Series B convertible preferred shares to BeiGene and Perceptive Advisors LLC at $10.55 apiece in the private placement. Leap expects to raise gross proceeds of about $27 million from the equity financing that will close on or before Jan. 8, subject to closing conditions.

The lead institutional investor will also receive a voting preferred share to elect one director on Leap's board. Raymond James & Associates Inc. was the placement agent for the equity financing.

Leap's DKN-01 is designed to target certain signaling pathways that are often implicated in cancer, enabling cancer cells to grow and divide and to suppress the immune system. A combination of DKN-01 and Merck & Co. Inc.'s blockbuster therapy Keytruda extended the lives of certain patients with a type of stomach cancer in a study testing the therapy.

Leap will study DKN-01 in combination with BeiGene's tislelizumab in patients with gastroesophageal junction — the point where the esophagus joins the stomach — and gastric cancer whose tumors expressed high levels of the DKK1 protein during the option period.